Eloralintide Research Peptide Pen (10 mg)

Eloralintide is a modified 37-residue amylin derivative (C201H319N49O65S2, ~4526.1 g/mol) developed under the code LY3841136. Its chain contains non-standard residues that extend its duration of action. In cell assays it preferentially activated the human AMY1 receptor, about 12-fold over the calcitonin receptor and 11-fold over the AMY3 receptor.

In diet-induced obese rats, eloralintide reduced food intake and lowered body weight in a dose-dependent way, mainly through fat mass loss, and pharmacokinetic studies in rats and monkeys showed long-acting exposure.

In published human research, once-weekly subcutaneous eloralintide was evaluated in phase 1 studies and in a 48-week, placebo-controlled phase 2 trial in adults with obesity or overweight, which reported mean body weight changes of -9% to -20% across dose arms versus -0.4% with placebo. Nausea and fatigue were the most frequently reported adverse events.

Supplied as a pre-mixed 10 mg / 1 mL injection pen for SubQ use in laboratory settings; 1 click delivers 0.1 mg.

Clinical Status:
Eloralintide is an investigational research peptide. It is not a GLP-1 receptor agonist and is not approved for medical use in any country; it remains restricted to experimental and laboratory research.

Evidence type:
Human RCT ✔ | Observational ☐ | Animal ✔ | In vitro ✔ | Regulatory ☐

Eloralintide mimics the pancreatic hormone amylin, which is co-secreted with insulin by beta cells. Amylin receptors are complexes of the calcitonin receptor with receptor activity-modifying proteins (RAMPs); eloralintide preferentially activates the AMY1 complex (calcitonin receptor + RAMP1). Amylin receptor signalling in hindbrain areas such as the area postrema is studied for its role in satiety and meal size, and structural modifications give the peptide a duration of action consistent with once-weekly dosing.

• Selective AMY1 Receptor Activation:
  In cell lines expressing single receptor types, eloralintide preferentially activated the human AMY1 receptor, about 12-fold over the calcitonin receptor and 11-fold over the AMY3 receptor. This selectivity makes it a useful tool for studying amylin receptor signalling with less concurrent calcitonin receptor activity, as described in the discovery and translational work published in 2025.
• Food Intake Research:
  In diet-induced obese rats, eloralintide reduced food intake in a dose-dependent manner. Amylin acts on hindbrain satiety circuits, including the area postrema, that are involved in ending a meal, and eloralintide is used to study how selective amylin receptor activation shapes meal size and energy intake in animal models.
• Body Weight Studies:
  Eloralintide lowered body weight in diet-induced obese rats. In a published 48-week phase 2 trial with once-weekly dosing, mean body weight changes from baseline ranged from -9% to -20% across dose arms, compared with -0.4% with placebo. These are group averages from a controlled study and are cited here for research context only.
• Fat Mass and Body Composition:
  In the rat studies, the body weight reduction came primarily from loss of fat mass. This makes eloralintide relevant for research questions on body composition, on how reduced energy intake is distributed between fat and lean tissue, and on amylin signalling in adipose tissue regulation in animal models.
• Once-Weekly Pharmacokinetics:
  Pharmacokinetic studies in rats and monkeys showed long-acting exposure, and in a 12-week phase 1 multiple ascending dose study exposure (AUC and Cmax) was dose proportional at steady state. The profile supports once-weekly dosing, which allows research protocols with stable, sustained amylin receptor engagement between doses.
• Tolerability Data for Study Design:
  In the 12-week phase 1 study, gastrointestinal events such as diarrhoea (10%), nausea (8%) and vomiting (4%) were infrequent and most events were mild. In phase 2, nausea and fatigue were the most common events and varied with dose and escalation scheme, data that help researchers plan gradual dose steps.
• Dose-Response Characterisation:
  Published studies cover a wide dose range: single doses of 0.04-12 mg in phase 1, and once-weekly fixed doses of 1, 3, 6 and 9 mg plus 3-9 mg and 6-9 mg escalation schemes in phase 2. The resulting dose-dependent data give a well-described reference frame for dose-response research.
• Amylin Pathway Reference Compound:
  With published in vitro, animal, phase 1 and phase 2 data, eloralintide serves as a reference compound for amylin receptor pharmacology, receptor subtype selectivity and appetite signalling studies. Its mechanism is distinct from GLP-1 receptor agonists, which makes it suitable for research that isolates the amylin pathway.

• Briere DA et al. Mol Metab 2025 Preclinical + phase 1
• Billings LK et al. Lancet 2025 Phase 2 trial
• Bhattachar S et al. Diabetes Obes Metab 2026 Phase 1 trial
• Bailey CJ et al. Peptides 2026 Review
• Alhazmi A, le Roux CW. Diabetes Obes Metab 2026 Review
• PubChem CID 175663130 (Eloralintide) Registry
• KEGG DRUG D12886 (Eloralintide) Registry
• MedChemExpress datasheet HY-P10798 Datasheet

Low-dose weekly research protocol

• Dose: 1 mg (10 clicks)
• Duration: 10 weeks (one pen)
• Frequency: Once weekly, subcutaneous (SubQ) with the pen
• Cycle Interval: Pause of at least 4 weeks before a repeat course
• Pen Coverage: 1 pen = 10 weekly doses
• Goal / Description: Entry dose matching the lowest once-weekly arm of the published phase 2 study. Basis: derived from once-weekly doses used in published studies; not a validated dose recommendation.

Step-up weekly research protocol

• Dose: 1 - 2 mg (10 - 20 clicks)
• Duration: 7 weeks: 1 mg for weeks 1-4, then 2 mg for weeks 5-7 (one pen)
• Frequency: Once weekly, subcutaneous (SubQ) with the pen
• Cycle Interval: Pause of at least 4 weeks before a repeat course
• Pen Coverage: 1 pen = 5 - 10 weekly doses
• Goal / Description: Gradual dose escalation, the approach used in the phase 2 study to improve tolerability. Basis: derived from once-weekly doses used in published studies; not a validated dose recommendation.

Standard weekly research protocol

• Dose: 3 mg (30 clicks)
• Duration: 3 weeks per pen; studied courses run 12-48 weeks
• Frequency: Once weekly, subcutaneous (SubQ) with the pen
• Cycle Interval: Pause of at least 4 weeks before a repeat course
• Pen Coverage: 1 pen = 3 weekly doses
• Goal / Description: Matches the 3 mg once-weekly arm of the published phase 2 study. Basis: derived from once-weekly doses used in published studies; not a validated dose recommendation.

No combination stack is suggested for Eloralintide in this catalogue:

• Eloralintide alone → the published phase 1 and phase 2 studies evaluated it as a single compound.
• Combination designs → no validated combination partner is offered in this catalogue.

⚠ Stacks are for experimental design only; not safety or efficacy guidance.

Eloralintide is an investigational compound. The effects below were reported in published research studies and are listed for research context only.

Effects reported in published studies:

• Nausea, the most common event in the phase 2 trial, more frequent at higher fixed doses and lower with gradual dose escalation.
• Fatigue, also among the most common events in the phase 2 trial.
• Decreased appetite, headache and fatigue in the 12-week phase 1 study.
• Diarrhoea, nausea and vomiting, reported as infrequent in phase 1.
• Most reported adverse events were mild in severity.

Long-term safety has not been established. Handle only under controlled laboratory research conditions.

• CAS #: 2883634-40-8
• Molecular Formula: C201H319N49O65S2
• Sequence (AA): N/A
• Molecular Weight: ~4526.1 g/mol
• PubChem CID: 175663130
• Half-Life: Long-acting; pharmacokinetics support once-weekly dosing
• Synonyms: LY3841136, LY-3841136
• Type: Synthetic research peptide (long-acting amylin analogue)
• Research Focus: Selective amylin (AMY1) receptor agonist studied for appetite, food intake and body weight regulation